Vectors Research Management LLC Has $546,000 Stock Holdings in Johnson & Johnson $JNJ

Vectors Research Management LLC lessened its holdings in Johnson & Johnson (NYSE:JNJ) by 14.6% in the 2nd quarter, HoldingsChannel.com reports. The institutional investor owned 3,577 shares of the company’s stock after selling 613 shares during the quarter. Vectors Research Management LLC’s holdings in Johnson & Johnson were worth $546,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of the business. GFG Capital LLC acquired a new stake in shares of Johnson & Johnson during the 2nd quarter valued at $35,000. Stone House Investment Management LLC acquired a new stake in shares of Johnson & Johnson during the 1st quarter valued at $47,000. 1248 Management LLC acquired a new stake in shares of Johnson & Johnson during the 1st quarter valued at $48,000. von Borstel & Associates Inc. acquired a new stake in shares of Johnson & Johnson during the 1st quarter valued at $49,000. Finally, Harvest Fund Management Co. Ltd acquired a new stake in shares of Johnson & Johnson during the 1st quarter valued at $52,000. Institutional investors and hedge funds own 69.55% of the company’s stock.

Insider Activity

In other news, EVP Jennifer L. Taubert sold 56,471 shares of the business’s stock in a transaction dated Thursday, September 4th. The shares were sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the transaction, the executive vice president owned 178,013 shares in the company, valued at approximately $31,652,491.53. The trade was a 24.08% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders own 0.16% of the company’s stock.

Johnson & Johnson Stock Performance

Shares of JNJ opened at $193.27 on Friday. The company has a market capitalization of $465.45 billion, a PE ratio of 18.65, a price-to-earnings-growth ratio of 2.27 and a beta of 0.40. Johnson & Johnson has a one year low of $140.68 and a one year high of $194.40. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.01 and a quick ratio of 0.76. The company’s fifty day moving average price is $180.49 and its 200 day moving average price is $164.86.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Wednesday, August 30th. The company reported $2.26 EPS for the quarter. The firm had revenue of $24.02 billion for the quarter. Johnson & Johnson had a net margin of 27.26% and a return on equity of 33.08%. As a group, analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 9th. Stockholders of record on Tuesday, November 25th will be issued a dividend of $1.30 per share. The ex-dividend date is Tuesday, November 25th. This represents a $5.20 annualized dividend and a dividend yield of 2.7%. Johnson & Johnson’s payout ratio is presently 50.19%.

Analyst Ratings Changes

A number of equities research analysts have issued reports on JNJ shares. Guggenheim raised shares of Johnson & Johnson from a “neutral” rating to a “buy” rating and lifted their target price for the company from $167.00 to $206.00 in a research note on Tuesday, September 23rd. Argus set a $210.00 price objective on shares of Johnson & Johnson in a research note on Wednesday. Wells Fargo & Company set a $212.00 price objective on shares of Johnson & Johnson and gave the company an “overweight” rating in a research note on Friday, October 3rd. Raymond James Financial lifted their price objective on shares of Johnson & Johnson from $174.00 to $209.00 and gave the company an “outperform” rating in a research note on Wednesday. Finally, Erste Group Bank raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating in a research note on Wednesday, July 23rd. Two analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and eight have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $199.59.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.